SCHOTT Pharma has a good start to fiscal year 2024 with sustained growth

SCHOTT Pharma, specializing in containment solutions and drug delivery systems, announces a promising start to the 2024 fiscal year. With a turnover of 232 million euros in the first quarter, the company recorded an increase of 8% compared to the previous year, taking into account constant currencies. This performance is accompanied by an EBITDA margin of 27.9% at constant currencies, signifying stability compared to last year. The share of high added value solutions is increasing, reaching 53%.

Andreas Reisse, CEO of SCHOTT Pharma, highlights the positive growth of both business segments and confirms the forecast for the fiscal year. The company continues to focus on innovation and expansion, including the development of high-capacity polymer syringes for portable injectors and the expansion of its global production network.

The Drug Delivery Systems (DDS) segment particularly contributed to revenue growth this quarter, with a significant increase in revenue driven by strong demand for prefillable syringes. Despite a slight decline in the Drug Containment Solutions (DCS) segment, the company maintains very good profitability thanks to a shift towards high value-added solutions and the economies of scale resulting from capacity expansion.

SCHOTT Pharma confirms its forecasts for the year with organic revenue growth between 9% and 11% and a stable EBITDA margin. The company remains guided by major trends in pharma and continues to develop new solutions for the secure storage and administration of injectable medications.